AdvisorShares Psychedelics ETF—— (—)Compass Pathways—— (—)Definium Therapeutics—— (—)GH Research—— (—)Helus Pharma—— (—)MIRA Pharmaceuticals—— (—)Neuphoria Therapeutics—— (—)Eli Lilly—— (—)Johnson & Johnson—— (—)AbbVie—— (—)Otsuka Pharmaceutical—— (—)Numinus Wellness—— (—)Optimi Health—— (—)PharmAla Biotech—— (—)Enveric Biosciences—— (—)Incannex Healthcare—— (—)Aurora Cannabis—— (—)Cronos Group—— (—)SNDL—— (—)Bright Minds Biosciences—— (—)PharmaTher Holdings—— (—)IM Cannabis—— (—)MariMed—— (—)Vireo Growth—— (—)

Loading prices

Thedrugreport

Published November 13, 2026 · Updated November 14, 2026

Psychedelic Fast-Track Shelved as FDA Stops New Vouchers - The Drug Report

Read the full story at Thedrugreport

The psychedelic fast-track is reportedly shelved, with no new FDA review vouchers since May and a dormant political council.

Post on X

Share this story

Surfaced by this Google Alert

Psychedelics